NCT05996133 Multifidus Cervicis Plane Block Vs. Sham Block For Posterior Cervical Spine Fusion Surgery
| NCT ID | NCT05996133 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Hartford Hospital |
| Condition | Cervical Spine Fusion |
| Study Type | INTERVENTIONAL |
| Enrollment | 38 participants |
| Start Date | 2023-12-12 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 38 participants in total. It began in 2023-12-12 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized, double-blinded, clinical trial is to assess the benefit of administering a Multifidus Cervicis Plane (MCP) block compared to a sham block as a method of postoperative pain control in patients undergoing posterior cervical spine fusion surgery. The main question it aims to answer is if the MCP block group will have reduced maximum pain scores during the first 24 postoperative hours compared to the sham block group. Participants will receive preoperative bilateral MCP blocks on the back of their neck using the standard of care local anesthetic solution that consists of 30 mLs 0.25% Bupivacaine + 0.5 mL (5 mg) preservative-free Dexamethasone + 0.1 mL Epinephrine (MCP block group). Researchers will compare the MCP block to the preoperative sham block which consists of injecting 3 mL of normal saline into the same area (Sham block group) to compare the postoperative pain scores between the groups as a main objective. The secondary objectives are: * Postoperative opioid consumption during hospitalization and at 2 weeks after discharge. * The amount and type of non-opioid analgesics used during hospitalization. * The occurrence of postoperative nausea and vomiting (PONV) and the use of antiemetics. * Hospital and Post Anesthesia Care Unit length of stay (LOS). * Monitor the safety of the study interventions during hospitalization and readmissions within 30 days of discharge. * Patient satisfaction with pain management and overall satisfaction with the surgery experience.
Eligibility Criteria
Inclusion Criteria: 1. Patients 40-80 years old, males and females, of any race and any ethnic group. 2. Patients are scheduled for elective primary posterior cervical spine fusion surgery (CSFS) to be performed by one of the spine surgeons in the study. 3. Ability to speak and read English 4. Patients with American Society of Anesthesiology (ASA) physical status score I- IV Exclusion Criteria: 1. Emergency posterior CSFS. 2. Revision surgery or history of previous cervical spine surgery 3. History of allergy to local anesthetics or steroids. 4. Patients who are coagulopathic at the time of surgery 5. Patients with contraindications to MCP blocks, including but not limited to anatomical abnormality or previous surgical intervention that limits or prevents receiving the blocks 6. Infection at the site of the block. 7. Weight \< 40 kg to avoid local anesthetic toxicity. 8. Patients on chronic or continuous opioid use of \> 50 MME (morphine milli-equivalent) per day for at least 30 days within 90 days prior to surgery. 9. Patients with a history of chronic inflammatory conditions such as multiple sclerosis 10. Refusal to participate or lack of providing the study consent
Contact & Investigator
Pranjali Kainkaryam, MD
PRINCIPAL INVESTIGATOR
Hartford Hospital
Frequently Asked Questions
Who can join the NCT05996133 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Cervical Spine Fusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05996133 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05996133 currently recruiting?
Yes, NCT05996133 is actively recruiting participants. Contact the research team at aseel.walker@hhchealth.org for enrollment information.
Where is the NCT05996133 trial being conducted?
This trial is being conducted at Hartford, United States.
Who is sponsoring the NCT05996133 clinical trial?
NCT05996133 is sponsored by Hartford Hospital. The principal investigator is Pranjali Kainkaryam, MD at Hartford Hospital. The trial plans to enroll 38 participants.